


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the March 2014 NCCN Trends™ Survey, which focused on Advanced Prostate Cancer. This survey was sent to U.S. and International users of NCCN.org.


DEMOGRAPHICS

Distribution of Respondent Types (n = 581)




Note: Percentages may not total 100 because of rounding.

Q1. Do you treat patients with advanced prostate cancer? (n = 552)



Q2. For patients with newly diagnosed metastatic Castration-Resistant Prostate Cancer, what is your preferred sequence of FDA approved therapies?

Please rank in order of utilization by selecting one per row. (n = 365)




Results: March 2014
ADVANCED PROSTATE CANCER

Q2. For patients with newly diagnosed metastatic Castration-Resistant Prostate Cancer, what is your preferred sequence of FDA approved therapies?

Please rank in order of utilization by selecting one per row.

By Geography


- 1st line
- 2nd line
- 3rd line
- 4th line
- 5th line
- 6th line



Q2. For patients with newly diagnosed metastatic Castration-Resistant Prostate Cancer, what is your preferred sequence of FDA approved therapies?

Please rank in order of utilization by selecting one per row.

By Practice Size




Q2. For patients with newly diagnosed metastatic Castration-Resistant Prostate Cancer, what is your preferred sequence of FDA approved therapies?

Please rank in order of utilization by selecting one per row.

By Practice Setting


- 1st line
- 2nd line
- 3rd line
- 4th line
- 5th line
- 6th line




Q2. For patients with newly diagnosed metastatic Castration-Resistant Prostate Cancer, what is your preferred sequence of FDA approved therapies?

Please rank in order of utilization by selecting one per row.

By Specialty




Q3. What product do you most often prescribe based on patient request? (n = 343)



Q3. What product do you most often prescribe based on patient request?

By Geography


- Sipuleucel-T
- Abiraterone acetate
- Enzalutamide
- Radium Ra223 dichloride
- Docetaxel
- Cabazitaxel



Q3. What product do you most often prescribe based on patient request?

By Practice Size


- Sipuleucel-T
- Abiraterone acetate
- Enzalutamide
- Radium Ra223 dichloride
- Docetaxel
- Cabazitaxel



Q3. What product do you most often prescribe based on patient request?

By Practice Setting


- Sipuleucel-T
- Abiraterone acetate
- Enzalutamide
- Radium Ra223 dichloride
- Docetaxel
- Cabazitaxel



Q3. What product do you most often prescribe based on patient request?

By Specialty

- Sipuleucel-T
- Abiraterone acetate
- Enzalutamide
- Radium Ra223 dichloride
- Docetaxel
- Cabazitaxel



NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Senior Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.org/patients - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.